U.S. Household Products Stock News

If you are wondering whether MetLife’s current share price reflects its true worth, this article explains how the market might be pricing the stock today. MetLife last closed at US$73.24, with returns of a 2.7% decline over 7 days, a 7.2% decline over 30 days, an 8.8% decline year to date, and a 12.0% decline over 1 year, compared with gains of 15.3% over 3 years and 41.2% over 5 years. These mixed returns sit against a backdrop of ongoing news coverage around the company’s position as a...

D-Wave Quantum (QBTS) has drawn fresh attention as investors reassess this US quantum computing provider after recent share price swings and a mixed return profile, including a 1-day gain alongside weaker performance over the past month and past 3 months. See our latest analysis for D-Wave Quantum. At the current share price of $18.94, D-Wave Quantum shows a 7-day share price return of 4.93% and a 90-day share price return of 15.82%. The 1-year total shareholder return remains very large,...

In late February 2026, Illumina, Inc. launched its TruPath Genome whole‑genome workflow and expanded Illumina Laboratory Services to support Florida State University’s new pediatric rare disease diagnostic lab with clinical sequencing and interpretation. Together, these moves pair higher‑resolution sequencing technology with real‑world clinical deployment, underscoring Illumina’s push to make advanced rare disease diagnostics more accessible and operationally efficient for hospitals and...

Roku (ROKU) just followed up a stronger fourth quarter with a slot at Bernstein’s “What’s next in tech?” forum, giving investors fresh context on its earnings, platform reach, and position as a neutral streaming aggregator. See our latest analysis for Roku. Roku’s recent 16.2% 7 day share price return and 22.2% 1 year total shareholder return sit against a weaker year to date share price return of 9.8% decline, suggesting momentum has picked up again around its earnings and platform...

Nuvation Bio (NUVB) just finalized a protocol amendment that advances its global SIGMA safusidenib study into Phase 3, widening access for high risk IDH1 mutant astrocytoma patients and drawing additional investor attention to upcoming earnings. See our latest analysis for Nuvation Bio. The share price, now at US$5.84, has a 7 day share price return of 7% and a 30 day share price return of 11%, but a 90 day share price return of a 22% decline. The 1 year total shareholder return is over 3x...

UroGen Pharma FY 2025 results set the stage for growth versus losses debate UroGen Pharma (URGN) closed out FY 2025 with Q4 revenue of US$37.8 million and a basic EPS loss of US$0.54, alongside a trailing twelve month loss of US$3.19 per share on US$109.8 million of revenue. The company has seen quarterly revenue move from US$24.6 million in Q4 2024 to US$37.8 million in Q4 2025. Over the same period, basic EPS ranged from a loss of US$1.05 in Q2 2025 to a loss of US$0.54 in the latest...

Why KLA (KLAC) is on investors’ radar right now KLA (KLAC) has drawn fresh attention after its recent share move, with the stock last closing at US$1,534.95 and delivering a 7.5% return over the past month and 29% in the past 3 months. See our latest analysis for KLA. Beyond the recent move, KLA’s momentum has been building, with a 7 day share price return of 3.2%, a 30 day return of 7.5% and a 1 year total shareholder return of about 124%, pointing to strong recent enthusiasm for the...

Interactive Brokers Group (NasdaqGS:IBKR) reports strong growth in client activity and trading volumes. The broker launches stablecoin funding for U.S. clients, allowing deposits in certain digital dollar tokens. The company highlights continued progress in brokerage technology and its inclusion in the S&P 500 Index. Interactive Brokers Group, trading at around $71.67, sits in a very different place than it did a few years ago, with a 1 year return of 43.0% and a 5 year return of 288.5%...

Immunome, Inc. recently presented at the TD Cowen 46th Annual Health Care Conference in Boston, updating investors on its oncology-focused pipeline and regulatory plans. A key highlight is the company’s push toward a New Drug Application for Varegacestat in desmoid tumors, alongside multiple upcoming solid tumor IND submissions and an FDA-cleared radioligand therapy trial. We’ll now examine how Immunome’s renewed oncology focus and advancing Varegacestat program might influence the company’s...

In February 2026, UMH Properties, Inc. reported its fourth-quarter and full-year 2025 results, with quarterly revenue rising to US$66.97 million but quarterly net income slipping to US$4.64 million, while full-year revenue climbed to US$261.75 million and net income to US$26.5 million. Alongside these mixed quarterly figures, UMH outlined plans for continued portfolio expansion and issued upbeat 2026 guidance, highlighting expectations for higher normalized FFO and earnings per share...

If you are wondering whether Bunge Global’s current share price lines up with its underlying worth, this article walks through the key numbers that matter for valuation. The stock recently closed at US$120.61, after a 0.6% decline over 7 days, a 5.9% gain over 30 days, and returns of 30.2% year to date, 73.1% over 1 year, 34.3% over 3 years, and 75.8% over 5 years. Recent coverage has focused on Bunge Global’s role in global agribusiness and food supply chains and how that positioning may...

Why Fresh Del Monte Produce (FDP) is back in focus Fresh Del Monte Produce (FDP) just reported fourth quarter and full year 2025 results, along with a fresh dividend declaration and an update on its completed share buyback. This gives investors several moving parts to assess at once. See our latest analysis for Fresh Del Monte Produce. The recent update on earnings, dividends and buybacks comes after a strong run in the share price, with a 16.84% 3 month share price return and a 47.18% 1 year...

NextEra Energy (NEE) has just completed a $2 billion composite units offering, combining future common stock purchase contracts with debentures, to fund energy and power projects and broader corporate needs, including debt repayment. See our latest analysis for NextEra Energy. At a share price of $92.71, NextEra Energy has seen a 30 day share price return of 5.47% and a 90 day share price return of 9.61%. Its 1 year total shareholder return of 33.29% and 5 year total shareholder return of...

Cullen/Frost Bankers (CFR) has drawn fresh attention after recent trading, with the share price closing at $140.21 and posting mixed short term returns while still showing gains over the past 3 months and year. See our latest analysis for Cullen/Frost Bankers. The recent 1 day share price return of 1.44% sits against a 7 day share price return of negative 1.35%. At the same time, the 90 day share price return of 13.93% and 1 year total shareholder return of 7.14% point to momentum that has...

Apogee Therapeutics reported a full-year net loss of US$255.84 million for 2025, with basic and diluted loss per share of US$4.22 as it continued to report no product revenue while investing heavily in its antibody pipeline. Alongside deeper losses, the company underscored upcoming clinical milestones for zumilokibart and other programs and filed a US$287.29 million shelf registration tied to an employee stock ownership plan, highlighting both capital needs and efforts to align employee...

Astera Labs has recently deepened its AI data center role by acquiring aiXscale Photonics, expanding with an Israel Design Center, and advancing its vendor‑neutral connectivity solutions through UALink participation and hyperscaler partnerships. This expansion into optical interconnects and closer collaboration with major cloud providers could reinforce Astera Labs’ position as a key infrastructure enabler in next‑generation AI data centers. We’ll now examine how the aiXscale Photonics...

ImmunityBio (IBRX) is back in focus after completing enrollment ahead of schedule in its Phase 2 ANKTIVA bladder cancer trial. Interim data show statistically significant response durability compared with BCG alone and no significant safety concerns. See our latest analysis for ImmunityBio. The latest ANKTIVA trial update arrives after a significant 3-month share price return of about 3.7x and a 416.83% year-to-date share price return, alongside a 245.70% 1-year total shareholder return. This...

Why Axon’s latest results caught investor attention Axon Enterprise (AXON) drew fresh interest after releasing fourth quarter and full year 2025 results, showing higher revenue alongside much lower net income, and pairing that with new 2026 guidance that calls for 27% to 30% revenue growth. See our latest analysis for Axon Enterprise. The earnings release and 2026 guidance arrived alongside a sharp short term move, with a 35.1% 7 day share price return and a 5.5% 1 day gain. The 3 year total...

Moody’s Corporation recently reported higher fourth-quarter and full-year 2025 results, continued its share repurchase program, filed a shelf registration for new debt securities, and earlier in February opened a new regional headquarters in Riyadh to deepen its presence in Saudi Arabia and the wider Middle East. Together, stronger earnings and the Riyadh regional hub highlight how Moody’s is pairing profit growth with a broader international footprint in a key capital‑markets region. We’ll...

NVR recently reported its fourth-quarter 2025 results, with earnings and Homebuilding revenue coming in ahead of consensus estimates despite weaker housing demand and affordability pressures. An interesting wrinkle is that, even with this earnings beat, analyst estimates for NVR have generally moved lower, pointing to a more cautious outlook on future performance. Next, we will examine how beating expectations amid softer housing demand shapes NVR's investment narrative for investors...

Setting the scene: Berkshire Hathaway’s recent performance snapshot Berkshire Hathaway (BRK.B) has seen its share price roughly flat over the past month, with a small 1 day decline and modest pullback over the past 3 months and year to date. See our latest analysis for Berkshire Hathaway. The recent 1 day share price return of a 4.91% decline at Berkshire Hathaway fits into a softer trend, with the 90 day share price return of a 5.23% decline contrasting with a 51.49% three year total...

Synopsys (NasdaqGS:SNPS) has appointed former Deloitte executive Peter A. Shimer to its board of directors and Audit Committee. Shimer brings long-tenured leadership experience and involvement in AI-driven cancer research to Synopsys' governance bench. Separately, Innatera has selected Synopsys tools for design validation of neuromorphic edge AI microcontrollers used at the sensor level. Synopsys, trading at $424.66, sits at the intersection of chip design tools and AI-centric computing,...

Taiwan Semiconductor Manufacturing (TSM) is back in focus after recent share price swings, with the stock showing a 1.5% decline on the day but a positive pattern over longer periods. See our latest analysis for Taiwan Semiconductor Manufacturing. Those short term share price moves sit within a stronger trend, with a 30 day share price return of 11.66% and a 90 day share price return of 26.37%. Meanwhile, the 1 year total shareholder return of 115.64% and very large 3 year total shareholder...

If you are wondering whether Pool at around US$222 still lines up with what it might be worth, you are not alone and this article is set up to help you frame that question clearly. The share price has moved 1.6% over the last 7 days, while returns sit at a 12.6% decline over 30 days, a 3.4% decline year to date, and declines of 34.4% over 1 year, 35.2% over 3 years and 28.3% over 5 years, which will affect how many investors view its growth potential and risk. Recent coverage around Pool has...